Rigel commences early stage trial of allergy drug
Allergic rhinitis causes chronic congestion and general inflammation of the upper respiratory tract in more than 59 million people in the US. The trial will compare R112 to
Allergic rhinitis causes chronic congestion and general inflammation of the upper respiratory tract in more than 59 million people in the US. The trial will compare R112 to
Pozen is now close to the receipt of a $20 million milestone windfall from GlaxoSmithKline, which is due to be paid to Pozen upon FDA approval of the
PV-10 is the company’s lead cancer agent and is being evaluated for safety and preliminary efficacy in 20 subjects with Stage III metastatic melanoma, which is the most
Benign prostatic hyperplasia (BPH) can restrict the flow of urine, resulting in urine retention, which can cause weakening of the bladder wall and the inability to empty the
The drug candidate prevents all types and strains of influenza virus from entering the airway epithelial cells, including avian influenza as well as para-influenza viruses. It aims at
Sinusitis is one of the most common conditions seen by primary care physicians, and according to the National Ambulatory Medical Care Survey, is the fifth most common condition
The drug is designed to concurrently inhibit the same molecular targets of breast cancer drug, Herceptin, and colon cancer drug, Erbitux. There is currently no single drug on
Three confirmed cases of multifocal leukoencephalopathy (PML), a rare demyelinating disease of the central nervous system, had previously been reported in patients treated with Tysabri (natalizumab), which Biogen
Previously, the efficacy of asthma drugs has been judged via measures of airflow obstruction, which the company suggests do not tell the whole story in terms of asthma
The first patients will commence treatment in early August at the Royal North Shore Hospital in Sydney and the Sydney Haematology and Oncology Clinics and further clinical centers